The estimated Net Worth of Global Investors Lp Viking ... is at least $7.67 Milione dollars as of 28 August 2023. Global Viking owns over 511,627 units of Inhibrx stock worth over $7,674,405 and over the last few years Global sold INBX stock worth over $0.
Global has made over 1 trades of the Inhibrx stock since 2023, according to the Form 4 filled with the SEC. Most recently Global bought 511,627 units of INBX stock worth $9,899,982 on 28 August 2023.
The largest trade Global's ever made was buying 511,627 units of Inhibrx stock on 28 August 2023 worth over $9,899,982. On average, Global trades about 511,627 units every 0 days since 2023. As of 28 August 2023 Global still owns at least 511,627 units of Inhibrx stock.
You can see the complete history of Global Viking stock trades at the bottom of the page.
Over the last 4 years, insiders at Inhibrx have traded over $27,711,393 worth of Inhibrx stock and bought 2,717,119 units worth $64,845,764 . The most active insiders traders include Global Investors Lp Viking ..., Capital Management, L.P.Kol... e Global Investors Lp Viking .... On average, Inhibrx executives and independent directors trade stock every 42 days with the average trade being worth of $1,598,400. The most recent stock trade was executed by Mark Lappe on 6 September 2024, trading 44,000 units of INBX stock currently worth $671,000.
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcinoma; INBRX-105, a tetravalent conditional agonist of programmed death-ligand 1 and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with locally advanced or metastatic solid tumors; and INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also provides INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company was founded in 2010 and is headquartered in La Jolla, California.
Inhibrx executives and other stock owners filed with the SEC include: